Wolverine Asset Management’s Astria Therapeutics ATXS Stock Holding History

Wolverine Asset Management’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-100	Closed	-$1.31K	–	1701
2025 Q4	$1.31K	Buy	+100	New	+$1.19K	﹤0.01%	1564

Wolverine Asset Management's ATXS Position: Q1 2026 in Review

Wolverine Asset Management sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 100 shares — an estimated $1.31K sold.

Wolverine Asset Management first reported a position in ATXS in Q4 2025 and held it in 1 quarter. The position peaked at $1.31K in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Wolverine Asset Management reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Wolverine Asset Management sold 100 Astria Therapeutics shares in Q1 2026, an estimated $1.31K.
Wolverine Asset Management first reported a position in Astria Therapeutics in Q4 2025 and held it in 1 quarter.
Wolverine Asset Management's Astria Therapeutics position peaked at $1.31K in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Wolverine Asset Management's 13F filing for Q1 2026, filed 4 May 2026.